F-1/A: Living Homeopathy IPO: Nasdaq Listing & HK Market Leader

Living Homeopathy International Ltd., a leading Hong Kong homeopathy service provider, is pursuing a Nasdaq Capital Market IPO of 1.25 million Class A ordinary shares.

Summary

• Living Homeopathy International Ltd. is offering 1,250,000 Class A ordinary shares, with an over-allotment option for an additional 187,500 shares, at an estimated price range of $4.0 to $6.0 per share.
• The company expects to receive net proceeds of approximately $3.84 million from the offering, assuming the midpoint price of $5.00 per share and no over-allotment exercise.
• Proceeds will be allocated: 40% for advertising, 30% for market and product development/marketing, and 30% for working capital and general corporate purposes.
• The company is a Hong Kong-based homeopathy service provider, holding the largest market share of approximately 35.8% in terms of homeopathic product sales revenue in Hong Kong in 2024.
• Revenue for the year ended March 31, 2025, decreased by 1.0% to $8,422,639 from $8,510,216 in 2024, primarily due to a significant drop in water filter sales.
• Net income increased by 7.8% to $812,130 in 2025 from $753,429 in 2024, despite a 36.3% decrease in income from operations.
• Gross profit increased by 1.0% to $6,423,394 in 2025, with gross margin improving to 76.3% from 75.0% in 2024.
• Operating expenses rose by 6.9% to $5,833,144 in 2025, largely driven by a 4,444.2% increase in legal and professional fees due to IPO-related costs and an 86.8% increase in other general and administrative expenses.
• The company operates as a Cayman Islands holding company with its primary operations conducted through its wholly-owned subsidiary in Hong Kong, Living Homeopathy Hong Kong, and has no operations or VIE structure in mainland China.
• The CEO, Mr. Ka Lun To, through his holding company, will control approximately 49.43% of total voting power after the offering, assuming no over-allotment exercise.

Sentiment

Score: 6

Explanation: The company shows strong market position and improving gross margins, with an increase in net income. However, the decline in overall revenue and operating income, coupled with significant IPO-related expenses and substantial dilution for new investors, presents a mixed financial picture. The regulatory and political uncertainties in Hong Kong and mainland China also add a layer of risk, balancing the positive market outlook.

Positives

• Living Homeopathy holds the largest market share in the Hong Kong homeopathy market, approximately 35.8% in terms of product sales revenue in 2024, indicating strong market influence.
• The company offers a diversified product portfolio across five categories (homeopathic remedies, co-remedies, classical flower remedies, personal care products, water filters) catering to varied customer demands.
• Established quality control practices are in place, including supplier certification requirements and regular product testing by Hong Kong STC, with key products eligible for the STC Certified Mark.
• Maintains long-term business relationships with the majority of its top 5 suppliers for over a decade, ensuring stable product supply and reducing negotiation costs.
• Experienced management and a mentor-mentee program with 687 practitioners holding Homeopathy First Aid Certificates, including 71 nutritional therapy practitioners, enhance service quality and marketing reach.
• Net income increased by 7.8% from $753,429 in 2024 to $812,130 in 2025.
• Gross profit increased by 1.0% to $6,423,394 in 2025, and gross margin improved from 75.0% to 76.3%.
• Net cash generated from operating activities significantly increased by 112.8% from $687,495 in 2024 to $1,463,328 in 2025.
• The Hong Kong T&CM market is projected to grow at a CAGR of 25.3% from 2024 to 2028, and the homeopathy market specifically is projected to grow at a CAGR of 12.0% over the same period.

Negatives

• Total net revenue decreased by 1.0% from $8,510,216 in 2024 to $8,422,639 in 2025, primarily due to a 55.1% decrease in sales of water filters and related products.
• Income from operations decreased significantly by 36.3% from $926,716 in 2024 to $590,250 in 2025.
• Operating expenses increased by 6.9% to $5,833,144 in 2025, largely due to a 4,444.2% increase in legal and professional fees and an 86.8% increase in other general and administrative expenses, primarily related to IPO costs and event fees.
• The company has substantial supplier concentration, with a limited number of suppliers accounting for a significant portion of total purchases and prepayments, posing risks if relationships change.
• Lack of written contracts with suppliers reduces predictability and could lead to order cancellations or modifications without penalty, making breach of contract claims challenging.
• The company has been subject to negative publicity, including a case of silver poisoning allegedly linked to its 'LIVING Colloidal Silver' product, which led to termination of sales for human use and potential reputational damage.
• The sustainability of the mentor-mentee program relies on strict compliance and effective enforcement of its code of conduct, with risks of unintentional misdemeanor or fraudulent misconduct challenging its legitimacy.
• There is a risk that the mentor-mentee program could be deemed a pyramid scheme under Hong Kong law, leading to significant penalties and requiring business model changes.
• New investors will experience immediate and substantial dilution of approximately $4.39 per Class A Ordinary Share, as the IPO price is significantly higher than the net tangible book value per share.
• The company does not anticipate paying cash dividends in the foreseeable future, meaning investors must rely on share price appreciation for returns.

Risks

• Operating in a competitive and rapidly evolving industry, making it difficult to evaluate prospects and manage growth effectively.
• Unfavorable publicity or consumer acceptance of products could reduce sales, as demonstrated by past negative publicity regarding 'LIVING Colloidal Silver'.
• The business is heavily regulated in Hong Kong, and new or tightened regulatory requirements and scrutiny could adversely affect business growth, financial condition, and results of operations.
• Potential product liability, false marketing, or other consumer claims could lead to substantial liabilities and regulatory penalties.
• Risk of enforcement action if the company, its employees, or mentors/mentees engage in improper marketing or promotion of products.
• The sustainability of the mentor-mentee program relies on strict compliance and effective enforcement, with risks from misconduct or non-compliance.
• Increasingly broad definitions of 'Pyramid Scheme' in relevant laws could lead to compliance pressure, increased costs, and adverse effects on business.
• Product recalls could incur significant and unexpected costs and damage reputation.
• The company may require substantial additional funding in the future, and there is no assurance that additional financing will be available.
• Damage to brand reputation could adversely affect the business.
• Increases in labor costs in Hong Kong and non-compliance with employment laws may adversely affect operations and results.
• Failure to manage and expand supplier relationships or procure products at favorable terms could harm business and growth prospects.
• Substantial supplier concentration with a limited number of suppliers poses risks if relationships change or obligations are not met.
• Lack of written contracts with some suppliers reduces procurement predictability and allows for order cancellations/modifications on short notice without penalty.
• Business depends on the continued efforts of senior management; loss of key executives could severely disrupt operations.
• Directors, management, and shareholders may be subject to negative publicity, claims, controversies, lawsuits, or legal/administrative proceedings.
• Reliance on proprietary information (trade secrets, know-how) without statutory protection in Hong Kong makes enforcement difficult and costly.
• Risk of infringing intellectual property rights of others and content restrictions of relevant laws.
• Proper functioning of information technology systems is essential; failure to maintain performance or security breaches could adversely affect business.
• Improper use, disclosure, or unauthorized access to customer data could harm reputation due to large data collection and processing.
• Lack of insurance (business interruption, product liability, key man life, network infrastructure) could expose the company to significant costs and business disruption.
• Financial and operating performance may be adversely affected by epidemics, natural disasters, and other catastrophes.
• Directors and officers, along with Class B shareholders, control a significant percentage of total voting power, potentially limiting minority shareholder influence.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to incorporation under Cayman Islands law.
• Inability to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.
• Directors are not subject to a term of office, making removal difficult without controlling shareholder consent.
• Reliance on dividends and distributions from the Hong Kong subsidiary for funding, with potential limitations on payments.
• Lack of effective internal controls over financial reporting may affect accurate reporting or fraud prevention.
• Cessation of foreign private issuer status would incur significant additional legal, accounting, and other expenses.
• As an emerging growth company, taking advantage of certain exemptions from disclosure requirements could make performance comparisons difficult.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Board of directors may decline to register transfers of Class A Ordinary Shares in certain circumstances (though unlikely for market transactions).
• Cayman Islands economic substance requirements may affect business and operations.
• PRC government may exercise significant oversight and discretion over Hong Kong operations, potentially intervening or influencing business, or imposing restrictions on fund transfers.
• Enactment of the Hong Kong National Security Law could impact the Hong Kong subsidiary.
• Political risks associated with conducting business in Hong Kong, including potential changes in economic, social, and legal environments.
• Uncertainties regarding future approvals from mainland China and Hong Kong authorities for U.S. listing and offering securities.
• More stringent requirements for domestic Chinese companies to share business and accounting records with foreign auditing firms could hinder the ability to offer securities.
• Difficulty for overseas shareholders and/or regulators to conduct investigations or collect evidence within mainland China.
• Additional costs and procedural obstacles in effecting service of legal process, enforcing foreign judgments, or bringing actions in Hong Kong.
• Potential impact from changes to the currency peg system in Hong Kong.
• No public market for Class A Ordinary Shares prior to this offering, and an active trading market may not develop.
• No guarantee that future audit reports will be prepared by PCAOB-inspected auditors, potentially leading to delisting under the HFCA Act.
• Recent SEC statements and proposed Nasdaq rule changes for emerging market companies could add uncertainties to the offering, business, share price, and reputation.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering and large insider holdings.
• Class A Ordinary Shares may be thinly traded, making it difficult to sell at or near ask prices.
• Market price for Class A Ordinary Shares may be volatile, potentially unrelated to operating performance.
• If securities or industry analysts do not publish research or reports, or if recommendations change adversely, market price and trading volume could decline.
• Substantial future sales or perceived potential sales of Class A Ordinary Shares could cause the price to decline.
• Uncertainty in the use of proceeds from this offering, as management has considerable discretion.

Future Outlook

The company plans to diversify sales channels by developing its online flagship store on Tmall Global to sell brand-name goods to consumers in mainland China, with key products being homeopathic co-remedies. It also intends to promote market regularization and standardization of the homeopathy market in Hong Kong and mainland China by working with regional institutes and medical schools. The company currently intends to retain all available funds and future earnings for business expansion and does not anticipate paying cash dividends in the foreseeable future.

Management Comments

• Mr. Ka Lun To, CEO and Chairman, has been authorized by the School of Homeopathy (UK) to teach relevant courses and conduct examinations for certain certificates and diplomas in Hong Kong.
• Management believes that existing resources, including cash generated from operations, will be sufficient to meet working capital and capital expenditure needs for the next twelve months.
• Management believes the mentor-mentee program is a suitable business model for marketing and sales, and for enhancing public awareness of homeopathy and its products.

Industry Context

The Traditional and Complementary Medicine (T&CM) market in Hong Kong is experiencing robust growth, expanding from $176 million in 2019 to $309.4 million in 2023 (CAGR 15.1%) and projected to reach $1,299.1 million by 2029 (CAGR 25.3% from 2024-2028). This growth is driven by increasing health consciousness, cultural acceptance of traditional practices, and government support, as well as rising prevalence of chronic diseases and an aging population. The homeopathy market in Hong Kong specifically grew at a CAGR of 4.8% from 2019 to 2023 and is projected to accelerate to 12.0% from 2024 to 2028. Living Homeopathy is a key player, holding the largest market share of 35.8% in 2024, benefiting from these trends and its diversified product portfolio. However, the industry faces challenges from a lack of education and awareness, intensified competition from other alternative medicines, and high entry barriers including capital and brand reputation.

Comparison to Industry Standards

• Living Homeopathy's 35.8% market share in the Hong Kong homeopathy market in 2024 positions it as the leading provider, indicating strong competitive standing compared to other local homeopathy service providers like HomeoCare HK, Vitality Centre, Integrated Medicine Institute, and Maya Health Institute.
• The company's gross margin of 76.3% in 2025 is robust, suggesting efficient cost management relative to its product pricing in the homeopathy sector.
• The projected CAGR of 12.0% for the Hong Kong homeopathy market from 2024 to 2028 indicates a healthy growth environment, which Living Homeopathy, as the market leader, is well-positioned to capitalize on, potentially outpacing smaller competitors.
• The company's reliance on long-term relationships with suppliers, without formal written contracts, is noted as a commercial judgment for flexibility, which differs from standard industry practices that often involve formal agreements for supply chain stability and risk mitigation.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in management's opinion, would have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• Sales of healthcare, personal care, and water filter products to Living Homeopathy Limited (Macau), an entity controlled by Mr. To, totaling $390,842 in 2025 and $368,969 in 2024.
• Purchases of certain healthcare products from Living Homeopathy Limited (Macau), an entity controlled by Mr. To, totaling $417,843 in 2025 and $456,773 in 2024.
• Lease expenses paid to Silver Link Limited, an entity controlled by Mr. To, for office premises, amounting to $184,780 in 2025 and $184,036 in 2024.
• Transfer of land and building ownership from Living Homeopathy Hong Kong to Mr. To on August 13, 2024, with a net carrying amount of $1,962,362, and the discharge of associated bank borrowings of $2,162,619 by Mr. To.
• Constructive dividends of $983,560 recorded in 2025 and cash dividends of $325,078 declared in 2024 to LTO Holdings Ltd., the controlling shareholder.
• Amount due to Ms. Hung (a shareholder) of $924,241 as of March 31, 2025, which is interest-free, unsecured, and repayable on demand.

Stakeholder Impact

• **Shareholders (New Investors)**: Will experience immediate and substantial dilution of approximately $4.39 per Class A Ordinary Share. Returns will depend on price appreciation as no dividends are anticipated in the foreseeable future. Subject to significant regulatory and political risks related to Hong Kong/PRC.
• **Shareholders (Existing/Controlling)**: Mr. Ka Lun To, through LTO Holdings Ltd., will retain significant voting power (approx. 49.43% after IPO), maintaining substantial influence over corporate decisions. Existing shareholders will benefit from the capital raise but face dilution from new shares.
• **Employees**: The company's success depends on attracting, retaining, and motivating qualified employees. Staff costs and employee benefits increased by 4.1% in 2025. The mentor-mentee program involves employees and offers sales commissions and product discounts.
• **Customers**: Benefit from a diversified product portfolio and established quality control. However, past negative publicity (LIVING Colloidal Silver) and potential product liability claims could impact trust. Expansion into mainland China via Tmall Global aims to broaden customer reach.
• **Suppliers**: Long-term relationships with major suppliers are crucial, but the lack of written contracts introduces risk regarding procurement predictability and potential disputes.
• **Regulatory Authorities (U.S. SEC, Nasdaq)**: The company is subject to U.S. reporting requirements and Nasdaq listing standards. Compliance with these, including internal controls and potential PCAOB inspection risks, will incur increased costs and management attention.
• **Regulatory Authorities (Hong Kong, PRC)**: The company operates in a heavily regulated environment in Hong Kong, with potential for increased scrutiny and new regulations. Uncertainties exist regarding future PRC government intervention or approval requirements for U.S. listing, which could significantly hinder operations.

Next Steps

• Listing Class A Ordinary Shares on the Nasdaq Capital Market under the symbol LHI, contingent upon final approval from Nasdaq.
• Diversifying sales channels by developing an online flagship store on Tmall Global for consumers in mainland China, focusing on homeopathic co-remedies.
• Promoting market regularization and standardization of the homeopathy market in Hong Kong and mainland China by collaborating with regional homeopathy-related institutes, medical schools, and other organizations.
• Retaining future earnings to re-invest in and finance the expansion of the business of Hong Kong operating subsidiaries.
• Management will have discretion in applying the net proceeds from the offering for advertising planning, market/product development, and working capital.

Key Dates

Recommendation

Living Homeopathy holds a strong market position in Hong Kong's growing homeopathy sector, with a diversified product portfolio and improving gross margins. The IPO aims to fund strategic growth initiatives like advertising and market expansion into mainland China. However, the company faces significant risks, including a recent decline in overall revenue and operating income, substantial dilution for new investors, and considerable regulatory and political uncertainties related to its Hong Kong operations and potential PRC government intervention. The lack of anticipated dividends in the foreseeable future means returns are solely dependent on capital appreciation, which is speculative given the volatility and thin trading potential. A 'hold' recommendation is appropriate, advising investors to monitor how the company navigates these risks and executes its growth strategies post-IPO before making further investment decisions.

Keywords

Homeopathy, Healthcare products, Personal care, Water filters, Hong Kong market, IPO, Nasdaq Capital Market, SEC filing, Alternative medicine, Health and wellness, Cayman Islands, F-1/A, Regulatory risk, China risk, Market share, Financial performance, Public offering